Cited by 479Opioid Use Disorder TreatmentSubstance Abuse Treatment and OutcomesPharmaceutical Practices and Patient Outcomes

The epidemiology of benzodiazepine misuse: A systematic review*

Open access
Votaw, Victoria R., Geyer, Rachel, Rieselbach, Maya M., McHugh, R. Kathryn·2019·Drug and Alcohol Dependence

Abstract

Background: Benzodiazepine misuse is a growing public health problem, with increases in benzodiazepine-related overdose deaths and emergency room visits in recent years. However, relatively little attention has been paid to this emergent problem. We systematically reviewed epidemiological studies on benzodiazepine misuse to identify key findings, limitations, and future directions for research. Methods: PubMed and PsychINFO databases were searched through February 2019 for peer-reviewed publications on benzodiazepine misuse (e.g., use without a prescription; at a higher frequency or dose than prescribed). Eligibility criteria included human studies that focused on the prevalence, trends, correlates, motives, patterns, sources, and consequences of benzodiazepine misuse. Results: The search identified 1,970 publications, and 351 articles were eligible for data extraction and inclusion. In 2017, benzodiazepines and other tranquilizers were the third most commonly used illicit or prescription drug in the U.S. (approximately 2.2% of the population). Worldwide rates of misuse appear to be similar to those reported in the U.S. Factors associated with misuse include other substance use, receipt of a benzodiazepine prescription, and psychiatric symptoms and disorders. Benzodiazepine misuse encompasses heterogeneous presentations of motives, patterns, and sources. Moreover, misuse is associated with myriad poor outcomes, including mortality, HIV/HCV risk behaviors, poor self-reported quality of life, criminality, and continued substance use during treatment. Conclusions: Benzodiazepine misuse is a worldwide public health concern that is associated with a number of concerning consequences. Findings from the present review have implications for identifying subgroups who could benefit from prevention and treatment efforts, critical points for intervention, and treatment targets.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.drugalcdep.2019.02.033

Cites

332 of 332 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Substance Abuse and Mental Health Services Administration, 2012 Comparing and evaluating youth substance use estimates from the National Survey on Drug Use and Health and other surveys. HHS Publication, Rockville, MD https://www.samhsa.gov/data/sites/default/files/NSDUH-M9-Youth-2012/NSDUH-M9-Youth-2012.pdf 30480921

Cited by

Sorted by citations

Authors
Votaw, V. R., Geyer, R., Rieselbach, M. M., & McHugh, R. K.
Affiliations
  • University of New Mexico (US)
  • McLean Hospital (US)
  • Harvard University (US)
Corresponding author
Votaw, Victoria R.
Venue
Drug and Alcohol Dependence
Publisher
Elsevier BV
Published
2019-07
Volume
200
Pages
95-114
ISSN
0376-8716 (ISSN-L)
OpenAlex
W2944251535
Cited by
479
References
332
Citations by year
2026: 45 · 2025: 65 · 2024: 74 · 2023: 119 · 2022: 61 · 2021: 60 · 2020: 46 · 2019: 8
FWCI
7.15
Type
journal article
Language
en
Open access
Locations
  • Drug and Alcohol Dependence (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institute on Alcohol Abuse and Alcoholism
  • McLean Hospital
  • National Institute on Drug Abuse
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
Keywords
benzodiazepine misuse, prescription drug misuse, prevalence, benzodiazepine overdose, substance use comorbidity, mental illness, illicit drug use, quality of life, criminality, prevention and treatment
MeSH terms
Benzodiazepines, Humans, Public Health, Quality of Life, Prevalence, Substance-Related Disorders, Prescription Drugs, Drug Overdose, Prescription Drug Misuse

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review